The Financial Supervisory Service (FSS) has introduced new disclosure requirements for pharmaceutical and biotech companies planning initial public offerings (IPOs). Companies must now provide detailed estimations of market size and clinical success probabilities, categorizing key assumptions into four areas to ensure transparency. Post-listing, firms must present a comprehensive research and development (R&D) record, including the history of discontinued projects, and clarify payment structures in contracts. These changes aim to enhance investor understanding and prevent previous issues, such as misleading disclosures that have led to market volatility, exemplified by the significant case involving Samchundang Pharm. Additionally, the FSS will promote consistent standards for public announcements to minimize confusion and misinterpretation in media reports.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.asiae.co.kr/en/article/stock-etc/2026073011131124867
